Sentence examples for a panel of transcripts from inspiring English sources

We created reporter constructs for a panel of transcripts including five predicted and 10 novel extensions that exhibited readthrough in both 0 2 hr embryos and S2 cells.

We used biological end points in uterine tissue and a signature pattern recognizing tool that identified coexpressed transcripts to develop and test a panel of transcripts in order to classify potentially estrogenic compounds using an in vivo system.

We have developed a panel of transcripts as biomarkers which, together with biological end points, might be used to screen and evaluate potentially estrogenic chemicals and infer mode of activity.

We have compiled a panel of 917 transcripts derived from more than 100 human signaling cascades and signaling networks.

For that reason, a panel of chemokine transcripts (or chemokine proteins) might be predicted to provide a measure of a broader complement of molecular influences that result in flares of disease activity or augmented inflammation in a target organ.

We compared gene expression patterns in primary bladder tumors with and without metastatic disease and by including previously published data from Riester et al. [ 20] we identified a panel of 12 transcripts significantly associated with disease outcome.

This analysis resulted in a panel of 11 transcripts (6 regulated by 2 μg Se/g and 5 regulated by Se deficiency), with an overall correlation coefficient of 0.9988 (P < 10-6) thaccountedted for 99% of the variation in liver Se concentration over the full range from 0 to 5 μg Se/g diet.

From their analysis, they derived a panel of estrogen-responsive transcripts as candidates for screening of estrogenic activity.

Our findings and the availability of the microarray data set will be useful in the development of a panel of biomarker uterine transcripts for future evaluation of modes of action and mechanisms of other potentially estrogenic chemicals.

Abot et al. (2013) derived a panel of 40 estrogen-responsive transcripts from published mouse uterus microarray data sets and also included evaluation of phenotypic end points, including uterine weights and the proliferative marker Ki67.

To increase sensitivity, some investigators are now testing strategies in which CTCs are identified by the presence of at least one mRNA transcript out of a panel of two or more tumour-associated transcripts (Taback et al, 2001; Ring et al, 2005).